ClinicaliQ Trial Snapshot
- Study of STP938 in Advanced Solid Tumours — Recruiting • Phase I • Oncology • NCT06297525.
- What is being tested: STP938 is an investigational drug being evaluated in a Phase 1 dose escalation and safety expansion study as a monotherapy treatment in patients with advanced solid tumours, with the aim of determining optimal dosing and safety profile.
- Patient eligibility overview: The trial recruits patients with advanced solid tumours who are typically treatment-experienced or unsuitable for standard therapies; specific inclusion/exclusion criteria are determined by the trial protocol and assessed at individual trial sites.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The Phase 1a part of the study is a dose escalation of STP938 as a monotherapy. The Phase 1b part of the study is a safety expansion cohort of STP938 as a monotherapy.
Eligibility Snapshot
- Main Inclusion Criteria: * Signed and dated informed consent, and able to comply with the study procedures and any locally required authorization. * Male or female aged ≥ 18 years. * Advanced disease not curable by available therapies and requires systemic therapy. * Histologically confirmed diagnosis of eligible cancer type. * Must have tumor tissue available for biomarker testing. * Measurable disease (Part 1) and measurable disease per RECIST (Part2) * Eastern Cooperative Oncology Group (ECOG) performance status ≤2. * Life expectancy > 3 months as assessed by the Investigator. * Adequate organ function (bone marrow, hepatic, renal function and coagulation). * All toxicities (except alopecia) from prior cancer treatments or procedures must have resolved to ≤Grade 1 or returned to baseline levels prior to enrollment. Main
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.